Story

Argenx Downgraded to Hold by Berenberg on Valuation After Sharp Rally

ENTHMSVIIDZHZH-TWJAKOHI
Aug 25, 20261 min read
Argenx Downgraded to Hold by Berenberg on Valuation After Sharp Rally
Text size
Background

Berenberg downgraded shares of biotech firm argenx to "hold" from "buy" on Tuesday, citing valuation concerns after a significant run-up in the stock price. The move comes despite the investment bank raising its price target on the company, signaling a positive view of its underlying business prospects but limited near-term upside for the shares.

Valuation Triggers Downgrade

The primary driver for the rating change is the stock's recent performance. According to Berenberg, argenx shares have rallied almost 50% since the firm initiated its "buy" rating in March.

Berenberg's analysts noted that this sharp increase has made the company's valuation less compelling. The downgrade reflects a view that much of the positive outlook is now priced into the stock, leaving less room for future gains for investors at current levels.

Vyvgart Outlook Strengthens

Sample IUX Markets – In-articleAd

Paradoxically, the downgrade was accompanied by an increase in Berenberg's price target for argenx, which was lifted to €925 from a previous €900. This optimism is tied to the company's flagship drug, Vyvgart.

The higher price target follows positive preliminary results from Vyvgart's Phase 3 ALKIVIA study in myositis, an inflammatory muscle disease. Based on this data, Berenberg has increased its peak sales forecast for Vyvgart to $14 billion. The firm stated that the trial results largely supported its prior analysis and strengthen the case for the drug's market expansion.

Market Impact

Despite the downgrade, argenx shares showed resilience in Tuesday's trading, rising 1.2% to €874.60. This followed a 4.2% decline in the previous session. The market's reaction suggests investors may be weighing the positive long-term drug pipeline developments against the more cautious near-term valuation assessment from the bank.

Read next

More on Stocks
Back to latest news

LATEST